查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1419141

前列腺癌治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按治疗类型、最终用户和地理位置

Prostate Cancer Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

摄护腺癌治疗市场预计将从2022年的147.67亿美元成长到2030年的284.25亿美元；预计2022年至2030年CAGR为8.5%。

前列腺癌是男性最常见的健康问题之一，尤其是老年男性（50岁以上）。前列腺癌最常见于肥胖且有前列腺癌家族史的男性。前列腺癌是一种无声的威胁，经常前列腺癌的发展没有明显的症状，因此早期发现这种癌症并不容易。通常，大多数前列腺癌起源于前列腺的周围区域。因此，为了使症状变得明显，癌症的大小必须达到它会对尿道造成压力，或者在某些情况下，转移引起的骨痛可能是晚期前列腺癌的首发症状。但是，任何年龄在50 岁或以上、出现下泌尿道症状、勃起功能障碍或血尿的个体考虑前列腺癌的可能性。前列腺癌是全球男性癌症死亡的第五大原因，也是第二常见的癌症。

强大的产品线为前列腺癌治疗市场的成长创造机会

目前前列腺癌治疗的前景广阔，拥有多种药物批准、丰富的产品线以及许多正在进行的临床试验。多种前列腺癌疗法正处于临床开发的不同阶段；製药巨头正在努力扩大其产品线，这是前列腺癌治疗市场的重大机会。以下提到了一些处于不同临床研究阶段的前列腺癌疗法：

序号 製造商 产品名称 临床试验阶段

1 阿斯利康 capivasertib 临床 II 期

capivasertib + 阿比特龙 CAPtello-281 临床 III 期

2 辉瑞PF-07220060+恩杂鲁胺临床I期

PF-06821497 + 恩杂鲁胺临床II期

TALZENNA 临床 III 期

3 礼来Abemaciclib临床III期

资料来源：ClinicalTrials.gov

使用化疗、标靶治疗和联合治疗治疗前列腺癌的强大产品线预计很快就会推动前列腺癌治疗市场的成长。

前列腺癌治疗市场根据治疗类型、最终用户和地理位置进行划分。前列腺癌治疗市场依治疗类型分为荷尔蒙治疗、化疗、免疫治疗、标靶治疗等。依最终用户划分，前列腺癌治疗市场分为医院、专科诊所等。

根据地理位置，前列腺癌治疗市场分为北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙、俄罗斯和欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳大利亚、东南亚和亚太地区其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲其他地区）。由于技术不断进步、前列腺癌病例数量不断增加、政府对不断增长的产品线的支持以及主要市场参与者致力于新产品和现有产品的开发，2022年北美在全球前列腺癌治疗市场中占据最大份额。然而，预计2022年至2030年亚太地区的CAGR最高。2022年，美国在北美前列腺癌治疗市场中占据最大份额。美国前列腺癌治疗市场的成长主要由发病率上升推动前列腺癌病例、产品发布和政府措施。公司推出的各种治疗前列腺癌的产品也促进了市场成长。例如，2023年6月，阿斯特捷利康和默沙东的Lynparza（olaparib）合併泼尼鬆或泼尼松龙和阿比特龙在美国被批准用于治疗疑似有害BRCA突变（BRCAm）转移性去势抵抗性前列腺癌（mCRPC）的成年患者）。此外，2023年11月，FDA批准了安斯泰来製药美国公司生产的恩杂鲁胺，用于治疗生化復发且转移风险高的非转移性去势敏感型前列腺癌（nmCSPC）。高风险BCR ）。除了皮肤癌之外，摄护腺癌是美国男性最常见的癌症之一。根据美国癌症协会估计，2023年将有约288,000例新发前列腺癌病例，预计约有34,700人死于摄护腺癌。根据同一来源，大约八分之一的男性在一生中会被诊断出患有前列腺癌。美国前列腺癌盛行率的不断上升以及人们对前列腺癌早期检测和早期治疗的认识不断增强，正在推动前列腺癌治疗市场的成长。

ClinicalTrails.com、疾病管制与预防中心 (CDC)、食品药物管理局 (FDA) 和国际标准化组织 (ISO) 是在准备前列腺癌治疗市场报告时参考的几个关键的主要和次要来源。

目录

第 1 章：简介

  • 研究范围
  • 市场定义、假设与限制
  • 市场区隔

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：前列腺癌治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：前列腺癌治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：前列腺癌治疗市场 - 全球市场分析

  • 前列腺癌治疗 - 全球市场概览
  • 前列腺癌治疗 - 全球市场和 2030 年预测

第 7 章：前列腺癌治疗市场 - 收入分析 - 依治疗方法，2020-2030 年

  • 概述
  • 荷尔蒙疗法
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 其他的

第 8 章：前列腺癌治疗市场 - 收入分析 - 按配销通路，2020-2030 年

  • 概述
  • 医院
  • 专科诊所
  • 其他的

第 9 章：前列腺癌治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 10 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 12 章：前列腺癌治疗市场 - 主要公司概况

  • Johnson and Johnson Services, Inc.

注意 - 将为以下公司列表提供类似信息

  • 拜耳公司
  • 阿斯利康
  • 安斯泰来製药公司
  • 礼来公司
  • 赛诺菲
  • 艾伯维公司
  • 默克公司
  • 诺华公司
  • 百时美施贵宝

第 13 章：附录

  • 词彙表
  • 关于 Insight Partners
  • 市场情报云
简介目录
Product Code: TIPRE00003423

The prostate cancer therapeutics market is expected to grow from US$ 14.767 billion in 2022 to US$ 28.425 billion by 2030; it is anticipated to record a CAGR of 8.5% from 2022 to 2030.

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years. Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Prostate cancer is the 5th leading cause of cancer death among men worldwide and the 2nd most commonly diagnosed cancer.

Strong Product Pipeline Creates Opportunity for the Growth of the Prostate Cancer Therapeutics Market

The current landscape for prostate cancer therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Multiple prostate cancer therapies are in various stages of clinical development; pharmaceutical giants are working to expand their pipeline, which is a major opportunity prevailing in the prostate cancer therapy market. A few of the prostate cancer therapies that are in different phases of clinical studies are mentioned below:

Sr. No. Manufacturer Product Name Clinical Trial Phase

1 AstraZeneca capivasertib Clinical Phase II

capivasertib + abiraterone CAPItello-281 Clinical Phase III

2 Pfizer PF-07220060 + enzalutamide Clinical Phase I

PF-06821497 + enzalutamide Clinical Phase II

TALZENNA Clinical Phase III

3 Lilly Abemaciclib Clinical Phase III

Source: ClinicalTrials.gov

A strong product pipeline for the treatment of prostate cancer using chemotherapy, targeted therapy, and combinational therapy is expected to fuel the growth of the prostate cancer therapeutics market shortly.

The prostate cancer therapeutics market is divided based on therapy type, end user, and geography. The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others.

Based on geography, the prostate cancer therapeutics market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global prostate cancer therapeutics market in 2022 owing to the increasing technological advancements, increasing number of prostate cancer cases, government support for the growing product pipeline, and major market players engaged in new and existing product developments. However, Asia Pacific is anticipated to register the highest CAGR from 2022 to 2030. The US held the largest share of North America's prostate cancer therapeutics market in 2022. The growth of the prostate cancer therapeutics market in the US is mainly driven by the increasing incidence of prostate cancer cases, product launches, and government initiatives. Various product launches by companies to treat prostate cancer also bolstered market growth. For instance, in June 2023, AstraZeneca and MSD's Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US for the treatment of adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). In addition, in November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc., which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). Other than skin cancer, prostate cancer is one of the most common cancers diagnosed in American men. According to the American Cancer Society Inc., it is estimated that in 2023, ~288,000 new cases of prostate cancer will be registered, and about 34,700 people are expected to die due to prostate cancer. As per the same source, ~ 1 in 8 men will be diagnosed with prostate cancer during their lifetime. This increasing prevalence of prostate cancer in the US and growing awareness about early detection and early treatment of prostate cancer in the US is fueling the growth of the prostate cancer therapeutics market.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and International Organization for Standardization (ISO) are a few key primary and secondary sources referred to while preparing the report on the prostate cancer therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Prostate Cancer Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Prostate Cancer Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Prostate Cancer Therapeutics Market - Global Market Analysis

  • 6.1 Prostate Cancer Therapeutics - Global Market Overview
  • 6.2 Prostate Cancer Therapeutics - Global Market and Forecast to 2030

7. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Therapy, 2020-2030

  • 7.1 Overview
  • 7.2 Hormonal Therapy
  • 7.3 Chemotherapy
  • 7.4 Targeted Therapy
  • 7.5 Immunotherapy
  • 7.6 Others

8. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Others

9. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Prostate Cancer Therapeutics Market Overview
    • 9.1.2 North America Prostate Cancer Therapeutics Market Revenue and Forecasts to 2030
    • 9.1.3 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Therapy
    • 9.1.4 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 9.1.5 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Prostate Cancer Therapeutics Market
        • 9.1.5.1.1 United States Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.1.2 United States Prostate Cancer Therapeutics Market, by Distribution Channel
      • 9.1.5.2 Canada Prostate Cancer Therapeutics Market
        • 9.1.5.2.1 Canada Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.2.2 Canada Prostate Cancer Therapeutics Market, by Distribution Channel
      • 9.1.5.3 Mexico Prostate Cancer Therapeutics Market
        • 9.1.5.3.1 Mexico Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.3.2 Mexico Prostate Cancer Therapeutics Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Prostate Cancer Therapeutics Market - Key Company Profiles

  • 12.1 Johnson and Johnson Services, Inc.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 12.2 Bayer AG
  • 12.3 AstraZeneca
  • 12.4 Astellas Pharma Inc
  • 12.5 Eli, Lilly, and Company
  • 12.6 Sanofi
  • 12.7 AbbVie Inc.
  • 12.8 Merck KGaA
  • 12.9 Novartis AG
  • 12.10 Bristol Myers Squibb

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud